Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial.

American journal of hematology·2026
Same author

Hematopoietic stem cell transplantation as a curative treatment for Nck-associated protein 1-like (HEM1) deficiency: A first case report.

Journal of human immunity·2026
Same author

Management of Iron Overload in Infants and Toddlers With Diamond-Blackfan Anemia Syndrome: A French-Italian Study.

American journal of hematology·2026
Same author

Retraction Notice to: Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.

American journal of hematology·2026
Same author

MMS22L is a novel key actor of normal and pathological erythropoiesis.

HemaSphere·2025

Related Experiment Video

Updated: May 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Germline TP53 Mutations Causing Diamond-Blackfan Anemia: A French Report.

Rafael Moisan1, Lydie Da Costa2,3,4, Ludivine David Nguyen2

  • 1Hematology Pediatric Department, CHU Lille, Lille, France.

Pediatric Blood & Cancer
|May 9, 2026
PubMed
Summary

TP53 deletions cause a rare form of Diamond-Blackfan anemia, presenting with anemia and neurological issues. Hematopoietic stem cell transplantation offers a potential cure for this complex genetic disorder.

Keywords:
DBAS‐OtherDiamond–Blackfan anemiaTP53hematopoietic stem cell transplantationinherited bone marrow failureneurological impairment

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Area of Science:

  • Genetics
  • Hematology
  • Pediatric Medicine

Background:

  • Diamond-Blackfan anemia (DBA) is a rare congenital erythroblastopenia primarily linked to mutations in ribosomal protein genes.
  • Recent research has identified gain-of-function mutations in the TP53 gene as a novel cause of DBA.

Purpose of the Study:

  • To describe two French patients with Diamond-Blackfan anemia caused by heterozygous TP53 deletion.
  • To highlight the clinical presentation, treatment response, and outcomes in TP53-associated DBA.

Main Methods:

  • Clinical case report of two patients with Diamond-Blackfan anemia.
  • Genetic analysis identifying heterozygous TP53 deletion (NM_000546.5: c.1077delA; p.(Ser362AlafsTer8)).
  • Assessment of clinical symptoms, laboratory findings, response to corticosteroid therapy, and outcomes after hematopoietic stem cell transplantation.

Main Results:

  • Both patients presented with normocytic anemia, transient neutropenia, and distinct neurological impairments.
  • Neither patient responded to corticosteroid treatment.
  • One patient achieved transfusion independence following hematopoietic stem cell transplantation from a matched sibling donor.

Conclusions:

  • Heterozygous TP53 deletion represents a complex genetic cause of Diamond-Blackfan anemia with unique clinical features.
  • TP53-associated DBA may not respond to standard corticosteroid therapy.
  • Hematopoietic stem cell transplantation is a potentially curative option for this specific DBA subtype, as demonstrated in one patient.